Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074563 | 0.88 | NOTUM (0.37) | NOTUML3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18707647 | 0.87 | NOTUM (0.39) | NOTUML3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1074263 | 0.86 | NOTUM (0.38) | NOTUML3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1075012 | 0.86 | KDM4E (0.34) | NOTUMKDM4EHPGDLMNAALDH1A1 | |
| SCHEMBL1907768 | 0.85 | HSD17B10 (0.39) | NOTUML3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1075463 | 0.83 | POLB (0.41) | KDM4EGRM5 | |
| SCHEMBL1081059 | 0.83 | SMN1; SMN2 (0.41) | NOTUMCYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL1900602 | 0.82 | TDP2 (0.42) | NOTUMCYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL1074565 | 0.82 | PDE2A (0.37) | NOTUMCYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL1903822 | 0.80 | GAA (0.36) | NOTUMCYP1A2CYP2D6CYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | claimed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | CBR3, NOX3, CBR1 | NOTUM 2781/4885L3MBTL1 3138/4885CYP1A2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.